The Foundation is proud to announce the award of $114,670 to Dr, Mark Souwidane for Enhanced Delivery (CED) for Diffuse Intrinsic Pontine Glioma.

The Foundation awards Oregon Health & Science University (and other institutions globally) an $8,800 Supplement for their Rapid Preclinical Development of a Targeted Therapy Combination for DIPG.

The Foundation awards $67,000 to Pharma Partner/Oregon Health & Science University Pilot Study.

The Foundation awards the DIPG Collaborative $50,000.

The Foundation awards Oregon Health & Science University (and other institutions globally) $28,000 for the Rapid Preclinical Development of a Targeted Therapy Combination for DIPG.